UNSPSC 51112032: Lenvatinib

Lenvatinib is an anti-cancer medication for the treatment of certain kinds of thyroid cancer and for other cancers as well. It acts as a multiple kinase inhibitor against the VEGFR1, VEGFR2 and VEGFR3 kinases.

UNSPSC 51112032 Lenvatinib is a Commodity code, but the recent state and local procurement activity indexed under this code shows no relevant solicitations for the pharmaceutical product itself. The most recent opportunities posted under this UNSPSC designation include a Williamson County, Texas purchasing department relocation notice (unrelated to procurement), a Seminole County, Florida IFB for naloxone and drug deactivation systems (a different pharmaceutical), a Tucson, Arizona Fire Department RFP for emergency medical services pharmaceuticals and supplies, Bernalillo County opioid settlement grants, Pinellas County drug standards for forensic analysis, and Collier County clinic and wellness services. These opportunities span distinct pharmaceutical and health-service categories that diverge substantially from lenvatinib's indication (thyroid and renal cell cancers). The code's tagging appears to reflect a misclassification in the state and local procurement databases rather than active demand for this specific oncology therapeutic.

State and local governments soliciting under this code designation are geographically dispersed across Florida (Seminole, Pinellas, Collier, Marion counties), Arizona (Tucson), Texas (Williamson), and New Mexico (Bernalillo). However, because the actual procurements linked to the code do not target lenvatinib or similar cancer therapeutics, the geographic and issuing-body signals carry limited value for vendors in oncology pharmaceuticals. The code shows minimal recent activity specifically aligned with lenvatinib distribution, wholesale acquisition, or institutional dispensing. A business development professional evaluating this code for lenvatinib positioning should verify the correct UNSPSC classification with state procurement offices, as current indexing suggests either database error or conflation with broader pharmaceutical commodity categories. The actual buying patterns visible in recent solicitations—emergency medical supplies, forensic drug standards, OTC wellness products—do not reflect institutional oncology procurement channels where lenvatinib would compete.